PM360

SEPTEMBER 21, 2023

The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

Marketing 98

Marketing Sales Physicians Patients 98

Pharmaceutical Technology

JULY 26, 2022

NPC is a rare inherited disease resulting from the body's inability to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances in various bodily tissues, including brain tissue.

Marketing 122

Marketing Transportation Leads Patients 122

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52